The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization

Diabetologia

Volumn 39, Issue 12, 1996, Pages 1655-1661

  Steiner, G ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

atherosclerosis; coronary angiography; diabetes mellitus; fenofibrate; interventional trial; lipoprotein

Indexed keywords

FENOFIBRATE; PLACEBO;

ADULT; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTILIPEMIC AGENTS; CLINICAL PROTOCOLS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PATIENT SELECTION; PROCETOFEN; WORLD HEALTH ORGANIZATION;

EID: 0342651348     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050630     Document Type: Conference Paper

References (20)

1. Steiner G (1985) Atherosclerosis, the major complication of diabetes. In: Vranic M, Hollenberg CH, Steiner G (eds) Comparison of type I and type II diabetes. Plenum Press, New York, pp 277-297
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444
3. Wilson PF, Kannel WB (1992) Epidemiology of hyperglycaemia and atherosclerosis. In: Ruderman N, Williamson J, Brownlee M (eds) Hyperglycaemia, Diabetes and Vascular Disease. Oxford University Press, Oxford, pp 21-29
4. Haffner SM, Stern MP, Rewers M (1993) Diabetes and atherosclerosis: epidemiological considerations. In: Draznin B, Eckel RH (eds) Diabetes and atherosclerosis. Elsevier, Amsterdam, pp 229-254
5. Fontbonne A, Eschwege E, Cambien F et al. (1989) Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 300-304
6. Austin MA (1991) Plasma triglyceride and coronary heart disease. Arterioscler Thromb 11: 3-14
7. Barrett-Connor E, Wingard DL (1983) Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study. Am J Epidemiol 118: 489-496
8. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
9. Frick MH, Elo O, Haapa K et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245
10. Tenkanen L, Pietila K, Manninen V, Manttari M (1994) The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med 154: 2714-2720
11. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH, Tenkanen L (1992) Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Diabetes Care 85: 37-45
12. Pyorälä K, Pedersen TR, Kjekshus J (1995) The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease. Diabetes 44 [Suppl 1]: 35A (Abstract)
13. Steiner G (1994) The dyslipoproteinaemias of diabetes. Atherosclerosis 110 [Suppl]: S27-S33
14. Shepherd J (1994) The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 110 [Suppl]: S55-S63
15. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW (1994) Effect of autonomic nervous system dysfunction on circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 24: 968-971
16. National Cholesterol Education Program, National Heart Lung and Blood Institute. National Institutes of Health (1991) Special Report. Report of the expert panel on population strategies for blood cholesterol reduction. Circulation 83: 2154-2232
17. Watts GF, Lewis B, Brunt JNH et al. (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339: 563-569
18. Lachin JM (1981) Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 2: 93-113
19. Davis CE (1991) Prerandomization compliance screening: a statistician's view. In: Schumaker SA, Schron EB, Ochene JK (eds) The handbook of health behavior change. Springer, Berlin Heidelberg New York, pp 340-347
20. Brown G, Albers J, John JJ, Fisher LD et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298